IRIS
MARTINI, ALBERTO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 50.251
AS - Asia 4.962
NA - Nord America 4.782
Continente sconosciuto - Info sul continente non disponibili 574
SA - Sud America 413
AF - Africa 90
OC - Oceania 11
Totale 61.083
Salva come PNG Salva come JPEG
Nazione #
IT - Italia 49.362
US - Stati Uniti d'America 4.456
SG - Singapore 2.158
CN - Cina 1.176
VN - Vietnam 733
FR - Francia 437
BD - Bangladesh 405
BR - Brasile 239
HK - Hong Kong 162
CA - Canada 110
FI - Finlandia 92
DE - Germania 84
CH - Svizzera 77
MX - Messico 64
AR - Argentina 60
GB - Regno Unito 54
JP - Giappone 50
IN - India 41
JM - Giamaica 35
CO - Colombia 30
EC - Ecuador 30
ZA - Sudafrica 30
IQ - Iraq 29
CR - Costa Rica 26
NL - Olanda 26
ID - Indonesia 25
PH - Filippine 21
RU - Federazione Russa 19
VE - Venezuela 19
GT - Guatemala 18
HN - Honduras 17
TR - Turchia 17
TH - Thailandia 16
CL - Cile 15
PK - Pakistan 15
DZ - Algeria 12
IE - Irlanda 12
KR - Corea 12
ES - Italia 11
JO - Giordania 11
PR - Porto Rico 10
SV - El Salvador 10
KE - Kenya 9
MA - Marocco 9
PL - Polonia 9
PY - Paraguay 9
SE - Svezia 9
TW - Taiwan 9
AU - Australia 8
KZ - Kazakistan 8
MY - Malesia 8
NP - Nepal 8
RO - Romania 8
SA - Arabia Saudita 8
UA - Ucraina 8
AT - Austria 7
NI - Nicaragua 7
BS - Bahamas 6
HR - Croazia 6
BB - Barbados 5
BY - Bielorussia 5
EG - Egitto 5
PE - Perù 5
SC - Seychelles 5
AE - Emirati Arabi Uniti 4
AZ - Azerbaigian 4
CW - ???statistics.table.value.countryCode.CW??? 4
LB - Libano 4
LT - Lituania 4
OM - Oman 4
QA - Qatar 4
SY - Repubblica araba siriana 4
UZ - Uzbekistan 4
BO - Bolivia 3
IL - Israele 3
KG - Kirghizistan 3
MM - Myanmar 3
PT - Portogallo 3
TT - Trinidad e Tobago 3
UY - Uruguay 3
AL - Albania 2
AM - Armenia 2
CG - Congo 2
CY - Cipro 2
DO - Repubblica Dominicana 2
GA - Gabon 2
GM - Gambi 2
KH - Cambogia 2
MK - Macedonia 2
NO - Norvegia 2
NZ - Nuova Zelanda 2
PA - Panama 2
PS - Palestinian Territory 2
RS - Serbia 2
SN - Senegal 2
TN - Tunisia 2
AD - Andorra 1
AG - Antigua e Barbuda 1
BA - Bosnia-Erzegovina 1
BE - Belgio 1
Totale 60.480
Salva come PNG Salva come JPEG
Città #
Genova 32.756
Genoa 9.444
Rapallo 4.070
Vado Ligure 2.565
San Jose 1.215
Singapore 1.042
Ashburn 685
Lauterbourg 411
Ho Chi Minh City 210
New York 203
Beijing 189
Hanoi 169
Hong Kong 146
Santa Clara 133
Helsinki 88
Los Angeles 88
Milan 76
Zurich 72
Bordighera 65
Council Bluffs 64
Frankfurt am Main 62
Rome 55
Chicago 47
Dallas 47
Tokyo 46
Phoenix 45
Haiphong 38
Buffalo 35
Mexico City 34
Da Nang 28
Atlanta 24
Tianjin 22
Orem 21
Houston 20
Kingston 20
Naples 20
Amsterdam 19
San José 19
Washington 19
San Francisco 17
Toronto 17
Brooklyn 16
Charlotte 16
Louisville 16
Seattle 16
São Paulo 16
City of London 15
Florence 15
Philadelphia 15
Montreal 14
Baghdad 13
Guatemala City 13
Nuremberg 13
Pasadena 13
Princeton 13
Cardiff 12
Denver 12
Guayaquil 12
Johannesburg 12
Columbus 11
Dublin 11
Garland 11
Guangzhou 11
Las Vegas 11
Newark 11
Turin 11
Cincinnati 10
Des Moines 10
Hải Dương 10
Miami 10
Queens 10
Quito 10
San Salvador 10
Amman 9
Chennai 9
Jacksonville 9
Kansas City 9
Bari 8
Biên Hòa 8
Bogotá 8
Bologna 8
Phủ Lý 8
The Bronx 8
Thái Nguyên 8
Baltimore 7
Bangkok 7
Boston 7
Calgary 7
Figino 7
Greenville 7
North Bergen 7
Rio de Janeiro 7
San Juan 7
Santiago 7
Shanghai 7
Almaty 6
Ankara 6
Boardman 6
Can Tho 6
Cape Town 6
Totale 54.944
Salva come PNG Salva come JPEG
Nome #
Novel automated system for Magnetic Resonance Imaging quantification of the inflamed synovial membrane volume in patients with juvenile idiopathic arthritis. 280
Relationship between damage accrual, disease flares and cumulative drug therapies in juvenile-onset systemic lupus erythematosus. 276
CD70 deficiency due to a novel mutation in a patient with severe chronic EBV infection presenting as a periodic fever 253
A longitudinal printo study on growth and puberty in juvenile systemic lupus erythematosus. 245
ADA2 deficiency (DADA2) as an unrecognised cause of early onset polyarteritis nodosa and stroke: a multicentre national study 243
Development and validation of a composite disease activity score for juvenile idiopathic arthritis 236
A Meta-Analysis to Estimate the Placebo Effect in Randomized Controlled Trials in Juvenile Idiopathic Arthritis 220
Malattia di Menetrier e gastropatia ipertrofica proteino-disperdente transitoria del bambino: due entità cliniche distinte? 217
Expert consensus on dynamics of laboratory tests for diagnosis of macrophage activation syndrome complicating systemic juvenile idiopathic arthritis 217
Delineating the application of ultrasound in detecting synovial abnormalities of subtalar joint in juvenile idiopathic arthritis 217
HRCT and pulmonary function tests in monitoring of lung involvement in juvenile systemic sclerosis. 213
Multi-antibody composition in lupus nephritis: Isotype and antigen specificity make the difference 208
Development and Initial Validation of the Macrophage Activation Syndrome/Primary Hemophagocytic Lymphohistiocytosis Score, a Diagnostic Tool that Differentiates Primary Hemophagocytic Lymphohistiocytosis from Macrophage Activation Syndrome 208
2016 Classification criteria for macrophage activation syndrome complicating systemic juvenile idiopathic arthritis: A European league against Rheumatism/American college of Rheumatology/Paediatric rheumatology international trials organisation collaborative initiative 208
Remission, minimal disease activity, and acceptable symptom state in juvenile idiopathic arthritis: Defining criteria based on the juvenile arthritis disease activity score 207
A proposal for a pediatric version of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index based on the analysis of 1,015 patients with juvenile-onset systemic lupus erythematosus. 205
Cross-cultural adaptation and psychometric evaluation of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR) in 54 languages across 52 countries: review of the general methodology 205
The Croatian version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR) 204
Genetic architecture distinguishes systemic juvenile idiopathic arthritis from other forms of juvenile idiopathic arthritis: Clinical and therapeutic implications 204
MRI versus conventional measures of disease activity and structural damage in evaluating treatment efficacy in juvenile idiopathic arthritis. 203

Dynamic Contrast-Enhanced Magnetic Resonance Imaging in Assessment of Disease Activity in Patients with Juvenile Idiopathic Arthritis 202
Candidate Genes in Patients with Autoinflammatory Syndrome Resembling Tumor Necrosis Factor Receptor-associated Periodic Syndrome Without Mutations in the TNFRSF1A Gene 202
Parent and child acceptable symptom state in juvenile idiopathic arthritis. 202
The EULAR/PRINTO/PRES criteria for Henoch-Schönlein purpura, childhood polyarteritis nodosa, childhood Wegener granulomatosis, and childhood Takayasu arteritis: ankara 2008. part ii: final classification criteria. 200
The Italian version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR) 196
Whole-body MRI in the assessment of disease activity in juvenile dermatomyositis 196
2016 ACR-EULAR adult dermatomyositis and polymyositis and juvenile dermatomyositis response criteria-methodological aspects 195
Intra-articular corticosteroids versus intra-articular corticosteroids plus methotrexate in oligoarticular juvenile idiopathic arthritis: a multicentre, prospective, randomised, open-label trial 194
Abatacept in children with juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled withdrawal trial. 193
Assessment of damage in juvenile-onset systemic lupus erythematosus: a multicenter cohort study. 193
Interferon-γ-dependent inhibition of B cell activation by bone marrow-derived mesenchymal stem cells in a murine model of systemic lupus erythematosus. 193
A randomized, placebo-controlled trial of infliximab plus methotrexate for the treatment of polyarticular-course juvenile rheumatoid arthritis 192
HLA-DRB1∗11 and variants of the MHC class II locus are strong risk factors for systemic juvenile idiopathic arthritis 192
A positive family history of psoriasis does not affect the clinical expression and course of juvenile idiopathic arthritis patients with oligoarthritis. 190
Agreement among musculoskeletal pediatric specialists in the assessment of radiographic joint damage in juvenile idiopathic arthritis. 189
Therapeutic approaches in the treatment of juvenile dermatomyositis in patients with recent-onset disease and in those experiencing disease flare: an international multicenter PRINTO study 189
A circulating reservoir of pathogenic-like CD4+ T cells shares a genetic and phenotypic signature with the inflamed synovial micro-environment 189
Advances in biomarkers for paediatric rheumatic diseases 189
Discordance between proxy-reported and observed assessment of functional ability of children with juvenile idiopathic arthritis. 188
Dissecting the heterogeneity of macrophage activation syndrome complicating systemic juvenile idiopathic arthritis 188
Disease status, reasons for discontinuation and adverse events in 1038 Italian children with juvenile idiopathic arthritis treated with etanercept 188
Differentiating PFAPA syndrome from monogenic periodic fevers. 186
A phase II, multicenter, open-label study evaluating dosing and preliminary safety and efficacy of canakinumab in systemic juvenile idiopathic arthritis with active systemic features. 185
A New Approach to Clinical Care of Juvenile Idiopathic Arthritis: The Juvenile Arthritis Multidimensional Assessment Report 181
Development and initial validation of the MS score for diagnosis of macrophage activation syndrome in systemic juvenile idiopathic arthritis 181
2011 American College of Rheumatology recommendations for the treatment of juvenile idiopathic arthritis: initiation and safety monitoring of therapeutic agents for the treatment of arthritis and systemic features 180
The role of imaging in juvenile idiopathic arthritis 180
Agreement between physicians and parents in rating functional ability of children with juvenile idiopathic arthritis. 179
2016 Classification Criteria for Macrophage Activation Syndrome Complicating Systemic Juvenile Idiopathic Arthritis: A European League Against Rheumatism/American College of Rheumatology/Paediatric Rheumatology International Trials Organisation Collaborative Initiative 179
Cryopyrin-associated periodic syndromes in Italian Patients: Evaluation of the rate of somatic NLRP3 mosaicism and phenotypic characterization 179
Clinical features, treatment, and outcome of macrophage activation syndrome complicating systemic juvenile idiopathic arthritis: a multinational, multicenter study of 362 patients. 178
Next-generation sequencing and its initial applications for molecular diagnosis of systemic auto-inflammatory diseases 178
Self epitopes shared between human skeletal myosin and Streptococcus pyogenes M5 protein are targets of immune responses in active juvenile dermatomyositis. 176
Development and testing of a hybrid measure of muscle strength in juvenile dermatomyositis for use in routine care 176
Development and validation of a composite disease activity score for measurement of muscle and skin involvement in juvenile dermatomyositis 176
Neurological disorders, other than stroke, associated with antiphospholipid antibodies in childhood. 174
Preliminary definition of improvement in juvenile arthritis. 173
Prediction of inactive disease in juvenile idiopathic arthritis: A multicentre observational cohort study 172
Preliminary core sets of measures for disease activity and damage assessment in juvenile systemic lupus erythematosus and juvenile dermatomyositis. 171
Phenotypic and functional characterisation of CCR7+ and CCR7- CD4+ memory T cells homing to the joints in juvenile idiopathic arthritis. 171
Aortic valve regurgitation as the presenting sign of Takayasu arteritis. 171
EULAR-PReS points to consider for the use of imaging in the diagnosis and management of juvenile idiopathic arthritis in clinical practice 171
Early changes in gene expression and inflammatory proteins in systemic juvenile idiopathic arthritis patients on canakinumab therapy 171
An international consensus survey of diagnostic criteria for macrophage activation syndrome in systemic juvenile idiopathic arthritis 170
Health-related quality of life in juvenile-onset systemic lupus erythematosus and its relationship to disease activity and damage. 169
A web-based collection of genotype-phenotype associations in hereditary recurrent fevers from the Eurofever registry 169
Development and initial validation of composite parent and child centered disease assessment indices for juvenile idiopathic arthritis. 169
Outcome and predicting factors of single and multiple intra-articular corticosteroid injections in children with juvenile idiopathic arthritis 168
Antiphospholipid antibody syndrome in pediatric patients. 168
Prevalence of anticardiolipin antibodies in juvenile chronic arthritis. 168
Evaluation of 21-Numbered Circle and 10-Centimeter Horizontal Line Visual Analog Scales for Physician and Parent Subjective Ratings in Juvenile Idiopathic Arthritis 168
Achievement of a state of inactive disease at least once in the first 5 years predicts better outcome of patients with polyarticular juvenile idiopathic arthritis. 167
Radiologic progression in patients with juvenile chronic arthritis treated with methotrexate. 167
Paediatric-onset systemic lupus erythematosus. 167
Hypocomplementemic urticarial vasculitis syndrome with severe systemic manifestations 167
Antinuclear antibody positive patients should be grouped as a separate category in the classification of juvenile idiopathic arthritis. 166
Criteria to define response to therapy in paediatric rheumatic diseases. 166
Relative responsiveness of condition specific and generic health status measures in juvenile idiopathic arthritis. 166
Bone marrow-derived mesenchymal stem cells induce both polyclonal expansion and differentiation of B cells isolated from healthy donors and systemic lupus erythematosus patients 166
A diagnostic score for molecular analysis of hereditary autoinflammatory syndromes with periodic fever in children 165
Prednisone versus prednisone plus ciclosporin versus prednisone plus methotrexate in new-onset juvenile dermatomyositis: A randomised trial 165
The PRINTO evidence-based proposal for glucocorticoids tapering/discontinuation in new onset juvenile dermatomyositis patients 165
A new short and simple health-related quality of life measure for paediatric rheumatic diseases: initial validation in juvenile idiopathic arthritis 164
Efficacy and safety of tocilizumab in patients with polyarticular-course juvenile idiopathic arthritis: results from a phase 3, randomised, double-blind withdrawal trial. 164
A randomized, double-blind, placebo-controlled trial of paracetamol and ketoprofren lysine salt for pain control in children with pharyngotonsillitis cared by family pediatricians 164
In vivo neutralization of human IL-6 (hIL-6) achieved by immunization of hIL-6 transgenic mice with a hIL-6 receptor antagonist 163
Performing trials in children with rheumatic diseases: Comment on the editorial by Lehman 163
Seeking insights into the EPidemiology, treatment and Outcome of Childhood Arthritis through a multinational collaborative effort: Introduction of the EPOCA study. 163
High prevalence of antiphospholipid antibodies in children with idiopatic cerebral ischemia 162
Phenotypic and functional characterization of switch memory B cells from patients with oligoarticular juvenile idiopathic arthritis 162
Phenotypic variability and disparities in treatment and outcomes of childhood arthritis throughout the world: an observational cohort study 162
Performance of different diagnostic criteria for familial Mediterranean fever in children with periodic fevers: Results from a multicenter international registry 162
Preliminary diagnostic guidelines for macrophage activation syndrome complicating systemic juvenile idiopathic arthritis. 161
Cytokines in juvenile rheumatoid arthritis. 161
Factors associated with achievement of inactive disease in children with juvenile idiopathic arthritis treated with etanercept. 161
The pattern of response to anti-interleukin-1 treatment distinguishes two subsets of patients with systemic-onset juvenile idiopathic arthritis. 161
Therapeutic approaches for the treatment of renal disease in juvenile systemic lupus erythematosus: an international multicentre PRINTO study. 161
Marked and sustained improvement 2 years after autologous stem cell transplantation in a girl with systemic sclerosis. 161
Factors associated with response to methotrexate in systemic-onset juvenile chronic arthritis. 160
Abatacept improves health-related quality of life, pain, sleep quality, and daily participation in subjects with juvenile idiopathic arthritis 160
Totale 18.508
Salva come PNG Salva come JPEG
Categoria #
all - tutte 199.242
article - articoli 196.705
book - libri 0
conference - conferenze 342
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 2.195
Totale 398.484
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20225.005 0 0 630 448 324 238 441 1.286 206 452 330 650
2022/20234.939 549 243 44 419 844 976 23 467 919 32 345 78
2023/20242.124 147 372 45 210 197 345 117 133 96 53 105 304
2024/20256.158 98 573 247 384 816 673 543 875 310 360 497 782
2025/202611.998 1.199 403 623 924 1.533 1.360 2.026 552 850 1.179 690 659
2026/20272.544 1.346 452 746 0 0 0 0 0 0 0 0 0
Totale 61.083